Tag Archives: regain

Weight Regain: What to Expect After Discontinuing Obesity Medications in Two Years

Posted on by
Reply

Weight loss drugs effectiveness

Weight loss medications, including Munjaro (tirzepatide), are effective when taken consistently.

Alan Swart / Alamy

A recent study involving over 9,000 participants revealed that individuals who discontinue weight loss medications often regain the weight lost within two years. This finding underscores the notion that obesity should be viewed as a chronic disease necessitating ongoing treatment.

“These medications are very effective; however, obesity is a chronic, relapsing condition,” explained Susan Jebb, who addressed the press at the University of Oxford. “Similar to hypertension medications, these treatments are likely needed for life.”

It’s evident that weight loss medications can significantly aid individuals in combating obesity, particularly newer GLP-1 medications mimicking gut hormones such as glucagon-like peptide 1—examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These drugs not only facilitate weight loss but also positively impact health metrics like blood pressure and cholesterol levels.

Nevertheless, many patients have ceased using GLP-1 medications due to side effects, including nausea, or a lack of availability triggered by heightened demand. “Approximately half of users discontinue these drugs within a year,” remarks Jebb.

While nations like the United States and parts of Europe permit long-term use of GLP-1 medications for weight control, frameworks like the UK’s National Health Service are restricting semaglutide usage for weight management based on cost-effectiveness evaluations over two years.

Previous studies indicate that individuals often regain weight post-semaglutide discontinuation. Yet, it remains unclear if this pattern extends to other weight loss interventions and the swift occurrence of weight gain upon cessation.

To investigate this, Jebb and colleagues reviewed 37 trials, combining data from over 9,000 participants, all classified as overweight or obese and using some form of weight loss medication (including GLP-1) for about 10 months, followed by a monitoring period of roughly 8 months.

From their analysis, the researchers noted that participants lost an average of 8.3 kilograms and experienced improvements in metabolic parameters like blood pressure, cholesterol, and blood glucose levels.

When examining weight patterns during the follow-up phase, the model suggested participants regained the average weight lost within 1.7 years after stopping their medications.

In trials specifically addressing semaglutide and tirzepatide, participants lost an average of 14.7 kilograms, yet it was anticipated they would regain all lost weight within a year and a half. Jebb points out that further insights are required to understand the accelerated weight gain associated with these drugs compared to others.

Additionally, the team discovered that the weight regain rate after ceasing weight loss drugs was about four times steeper than that observed following the termination of a structured behavioral weight loss program, which typically emphasizes healthy eating and increased physical activity.

However, this disparity may be attributed to the greater motivation for weight loss among individuals participating in behavioral programs compared to those relying on medications.

Another factor contributing to this swift weight regain may be the appetite suppression induced by these drugs. Users often report significant increases in hunger and cravings upon discontinuation, possibly leading to rapid weight resurgence, as noted by Taraneh Soleimani from Pennsylvania State University.

Yet, a separate analysis suggested that offering behavioral support during the follow-up phase did not effectively curb weight gain. Soleimani emphasizes that more research is essential to determine optimal strategies for supporting individuals transitioning off weight loss medications.

What Jebb’s research illustrates, according to her, is the critical need to consider obesity as a long-lasting condition. “Weight loss drugs demonstrate effectiveness, and weight regain is prevalent upon cessation,” states Professor Soleimani. “These results confirm obesity as a chronic condition that requires prolonged treatment.”

Topics:

  • obesity/
  • weight loss drugs

Source: www.newscientist.com

Can AI Agents Regain Control of the Internet from Big Tech?

Posted on by
Reply

Autonomous AI agents may soon communicate across the Internet

Outflow Designs/Istockphoto/Getty Images

What does the future of the internet hold? As AI companies evolve, previously open web spaces are being overtaken by digital silos controlled by commercial AI models, sidelining enthusiasts and small businesses. In response, a coalition of grassroots researchers is determined to champion an open approach to AI.

Central to this effort is the notion of AI “agents.” These are software programs that navigate the web and interact with online platforms based on human directions, such as planning holidays and making bookings. Many perceive these agents as the next stage of evolution following services like ChatGPT, yet they face significant challenges in functionality. This is largely due to the web’s design, which favors human interaction; thus, developers are recognizing that AI agents require specialized protocols to effectively engage with online content, services, and each other.

“The objective is to establish infrastructure that facilitates communication among bots, much like software does,” explains Catherine Frick from Staffordshire University, UK.

Several competing solutions to this challenge have emerged. For instance, Anthropic, the creators of the Claude chatbot, have introduced the Model Context Protocol (MCP), which standardizes the way AI models connect to various data sources and tools. In April, Google announced its own take with the Agent2Agent (A2A) protocol, offering a distinct approach to this concept.

While these methods share similarities, they have important differences. MCP focuses on standardizing AI models’ connections to external data repositories and tools, creating a secure universal channel for two-way communication—akin to having a phone number or email for messaging. In contrast, A2A expands on this by enabling autonomous agents to discover one another, exchange information, and collaborate on tasks.

For instance, you can link your AI chatbot to the code-sharing platform GitHub via MCP, yet Google asserts that A2A could enable agents to manage job interviews, conduct calls, perform background checks—all in one streamlined process, with the agent team operating simultaneously.

However, as these protocols originate from major tech companies, concerns arise that the creators of the most successful protocol might leverage it for their own commercial gain. The MCP model necessitates oversight from a central server for connections, whereas A2A comes with its own costs, assuming that authorized agents will cooperate.

“We want to prevent an ‘Agent Internet’ from evolving into yet another ‘silo alliance,'” warns Gawee Chan, who serves as chairman of the AI Agent Protocol Group. Founded in May as part of the World Wide Web Consortium (W3C) Standards Organization, Chan emphasizes the importance of inclusivity in developing this new layer of the Internet. “If we genuinely believe that AI is a transformative technology for human society, we need an open, neutral community to guide protocol development, ensuring that its future is shared by all companies, not just a select few,” he states.

In pursuit of this goal, Chang has initiated an open-source alternative to the Big Tech Agent Protocol with the Agent Network Protocol (ANP), which predates both MCP and A2A. ANP facilitates AI agents in discovering each other and establishing identities across the web, reminiscent of the early days of the internet, when individuals created personal websites and email accounts independent of large tech intermediaries. This autonomy allows ANP-driven models to function without a central authority, enabling direct communication between distinct AI models on the same device without needing internet verification.

Flick supports the emergence of open-source, non-commercial alternatives for Agent AI. “Essentially, our aim is to restore the fundamental principle of democratization to the Internet, which is how it all began,” she remarks. Without such alternatives, she warns that tech giants could create “walled gardens” reminiscent of the challenges seen in app stores and social media platforms. “If we rely on major corporations for this, they will execute it primarily to maximize profits,” she cautions.

Google claims that its protocols are designed for universal benefit. “We will continue to enhance [A2A] to tackle real-world challenges businesses face in deploying agent frameworks. At its core, it’s structured for the future’s demands,” says Rao Sarapaneni from Google Cloud.

“We have always believed in ensuring that advancements in AI serve everyone,” adds Theo Chu, an anthropologist. “When I developed MCP, I recognized that one key strategy to avoid fragmentation and vendor lock-in—which hampers the advancement of other technologies—was to make it open-source.”

Chu asserts that MCP is integrated across major platforms, including Microsoft, OpenAI, and Google. “The success of MCP will stem from its ability to expand choices rather than restrict them,” she notes. “The collective value of the ecosystem is increased for everyone.”

The W3C Group is eager to collaborate with all stakeholders to establish technical standards industry-wide, but no specific timeline has been set. “Ultimately, our focus isn’t on the triumph or failure of any one protocol but rather on the holistic growth of the agent ecosystem.”

Topics:

Source: www.newscientist.com

Retinal Implants Regain Vision in Blind Mice

Posted on by
Reply

Retinal damage can result in blindness

bsip sa/alamy

Retinal implants have shown potential in restoring vision in blind mice, indicating that they may eventually help those with conditions like age-related macular degeneration, where photoreceptor cells in the retina deteriorate over time.

Shuiyuan Wang from Fudan University in China and his team developed a retinal prosthesis composed of metal nanoparticles that replicate the function of lost retinal cells, converting light into electrical signals to be sent to the brain.

In their experiments, the researchers administered nanoparticles into the retinas of mice that had been genetically modified to be nearly completely blind.

They restricted water access for three days to both the modified blind mice and those with normal vision. Subsequently, they trained all mice to activate a 6cm wide button on a screen to receive water.

Following training, each mouse underwent 40 testing rounds. The fully sighted mouse pressed the button successfully 78% of the time. Mice with implants achieved a 68% success rate, while untreated blind mice only managed 27%. “That presents a very noticeable effect,” stated Patrick DeGenard, who wasn’t involved in the research but is affiliated with Newcastle University in the UK.

After 60 days, researchers observed minimal signs of toxicity from the implants in the mice. However, Degenaar emphasized the need for long-term safety data, stating, “For clinical application, extensive animal testing lasting approximately five years will be necessary.”

“Patients with age-related macular degeneration and retinitis pigmentosa could benefit from this prosthetic,” noted Leslie Askew from the University of Surrey, UK, who was not part of the study.

Degenaar also remarked that justifying this solution for age-related macular degeneration patients is complex, as they possess a degree of vision that may not warrant the risks associated with implanting prosthetics.

Furthermore, he noted that mice generally have inferior vision compared to humans, raising uncertainty about how beneficial the findings will be for people until comprehensive clinical trials are conducted.

Topic:

Source: www.newscientist.com

Mastering Technology: How to regain control with these 5 strategies, from email to AI

Posted on by
Reply

Enhancing AI’s Efficiency

Innovations in AI have come a long way since I first used ChatGPT to generate emails two years ago. Take Google’s experimental “AI research assistant,” notebook LM, for example. This tool goes beyond text prompts by allowing users to upload various types of content like videos, links, and PDFs. It organizes your original sources and notes, provides content overviews, answers questions, and even creates podcast-like summaries. As AI tools evolve, we can anticipate more advanced features integrated into everyday software. However, it’s crucial to remember to fact-check and verify the information generated by AI.

Escape Algorithmic Constraints

If you find yourself trapped in a repetitive cycle of music or TV recommendations, it’s time for a change. Platforms like Netflix offer options to reset your viewing history, allowing you to start fresh with new recommendations. Similarly, diversifying your listening habits on Spotify can broaden the range of choices offered to you. Utilize features like Private Session mode or Exclude from Preference Profile to customize your content recommendations based on your preferences.

Identifying AI-Generated Videos

As text-to-video tools become more prevalent, the rise of AI-manipulated videos, known as “deepfakes,” is inevitable. Keep an eye out for watermarks indicating AI generation and be cautious of anomalies like incorrect anatomy or physics in videos. Contextual clues are key in spotting AI-generated content, so stay alert for any content that seems too outlandish or suspicious.

Verify, Watch, and Backup

Incidents of “snatch theft” are on the rise, with thieves targeting mobile phones for resale overseas. While prevention is challenging, ensure to backup important data on your device to mitigate potential losses. Enable automatic syncing to cloud services or manually backup media files through device settings to safeguard your data. In the event of theft, having backup copies ensures that vital information is not lost.

Source: www.theguardian.com

The reasons behind weight regain after losing it: a new understanding emerging

Posted on by
Reply

Losing weight can be difficult

Tero Vesalainen/Getty Images

Obese people often lose weight but gain it back, but this may be partly due to permanent changes in the DNA within fat cells, a discovery that could one day lead to new treatments. may lead to.

Approximately 85% of overweight or obese people lose at least one-tenth of their body weight get it back within a year.

Part of the reason is that low-calorie diets are difficult to maintain over long periods of time, but that likely plays a relatively small role, he said. Laura Katarina Hinte at the Federal Institute of Technology Zurich, Switzerland. “There's no way we all don't have enough willpower to keep off the weight we lose.”

Research shows that the brain interprets a sudden drop in body fat as dangerous; It responds by reducing the body's energy expenditure.

To learn more about this process, Hinte and his colleagues sampled adipose tissue from 20 obese patients, who were about to undergo bariatric surgery (a procedure that shrinks the stomach to help you feel full more quickly) and who had at least lost weight. It was analyzed two years later. 1/4 of the original weight. They also examined adipose tissue in 18 people with healthy weight.

Researchers have sequenced a type of genetic molecule called RNA that codes for proteins in fat cells. They found that obese people had increased or decreased levels of more than 100 RNA molecules compared to healthy weight people, and these differences persisted two years after weight loss.

These changes appear to exacerbate inflammation and disrupt the body's state. Fat cells store and burn fat, both of which increase the risk of future weight gain, according to team members. Ferdinand von Mayenalso at the Federal Institute of Technology Zurich.

To examine whether these RNA changes could cause rebound weight gain, the researchers first determined that similar changes persisted even after obese mice lost weight. These mice, as well as mice of healthy weight, were then fed a high-fat diet for one month. The previously obese mice gained an average of 14 grams, while the other mice gained only 5 grams.

The researchers also found that fat cells from previously obese mice took up more fat and sugar than fat cells from other mice when cultured in a laboratory dish. Taken together, these results show how obesity-related RNA changes can increase future weight gain, von Mayen said.

Finally, the research team found that molecular tags, or epigenetic marks, on the DNA within fat cells appear to drive RNA changes associated with obesity. They change RNA levels by changing the structure of the DNA that encodes it.

Although the study did not look for these molecular tags in the people studied or see if they regained the weight they lost, the findings likely apply from mice to humans. states. henriette kirchner At the University of Lübeck, Germany.

This is based on similarities between the physiology of these species and how the environment can change the way their genes work, known as epigenetics, she says. In the coming decades, Kirchner says drugs that target epigenetics could help treat obesity.

topic:

Source: www.newscientist.com

Five children born deaf regain their hearing through gene therapy

Posted on by
Reply

Gene therapy involves administering normal copies of the mutated gene that causes a particular disease.

nobeastsofierce/Shutterstock

Five Chinese children born deaf have received gene therapy that provides them with a healthy copy of a mutated gene, allowing them to hear in both ears. Although the children have varying degrees of hearing loss, all can now hear and localize sounds at conversational volume.

Six months after treatment, the five children’s hearing was about 50 to 60 percent of normal levels, team members say. Chen Yi Chen “They get confused when we whisper, but normal conversation is fine,” he said at the Massachusetts Eye and Ear Infirmary in Boston. “We’re very happy.”

In the first phase of the trial, which began in 2022, the team gave another group of six children in China the gene therapy in just one ear. Five of the six children had their hearing restored in the treated ear, with continued improvement, Chen said.

The team expects to see further progress in the second group of five children. “The progress we’re seeing now isn’t the peak,” Chen says. “We expect to see even more progress.”

The trial in China is the first of several ongoing trials around the world. She lives in the UK with her two children. There have also been reports in the United States of people regaining hearing in one ear after undergoing gene therapy.

“The tests are all pretty much the same.” Manohar Bans Doctors from Cambridge University treated two children in the UK.

All of the children in these trials were born with hearing loss because they carry a mutation in both copies of the gene for a protein called otoferin, which plays a key role in synapses, or connections, between the hair cells in the ear that detect sound and the nerves that transmit signals to the brain. The mutation affects the protein, blocking the transmission of signals.

Between 2 and 8 percent of children worldwide who are born with hearing loss are thought to have this condition, known as DFNB9.

Both parents of a child with DFNB9 have normal hearing if they each have just one mutant copy of otoferlin. These couples are often unaware that they have a one in four chance of having a child that is born deaf.

Gene therapy relies on the help of a virus called AAV to deliver a working version of the otoferlin gene to hair cells. Due to the gene’s large size, it needs to be split and put into two separate viruses.

The virus cocktail is injected into the inner ear, and the complete gene is reconstituted in cells that receive both halves. The DFNB9 trial marks the first time that so-called dual AAV gene therapy has been used to treat humans.

“This is a major technological advance,” Chen says, “and we hope that this technology will be widely used to treat other genetic diseases.”

The clinical trials will begin by treating one ear at a time because half the dose of AAV is needed, reducing the chance of adverse events, he says. No serious adverse events have been reported in any of the trials.

Chen’s team now plans to treat the other ears of the first group of children. This could be difficult because an immune response to the initial AAV injection could block gene delivery, but Chen believes it is possible.

Treating other inherited hearing loss is more difficult because some of the structures inside the ear degenerate. With DFNB9, all of the structures remain intact. “You only need to repair one element,” Chen says.

Some people believe that hearing loss is not a disease that needs treatment, Martin MacLean The position of the National Society for Deaf Children. Families should be free to make their own informed decisions.

“Parents and young people need to be aware of all the risks and, above all, understand that hearing loss in itself does not prevent people from living a happy and fulfilling life,” he says.

topic:

Source: www.newscientist.com